Inactive Instrument

Highlights Clarus Therapeutics Holdings, Inc.

Equities

CRXT

US18271L1070

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	19/08/22	AQ
Clarus Therapeutics Posts Higher Revenue in Q2; Planned 40% Workforce Cut to be Completed in August	18/08/22	MT
Clarus Therapeutics Posts Higher Revenue in Q2	18/08/22	MT
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/08/22	CI
Clarus Therapeutics Gets US Patent for Testosterone Replacement Product	18/05/22	MT
CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	16/05/22	AQ
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Clarus Therapeutics Holdings, Inc Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)	28/04/22	CI
CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	31/03/22	AQ
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	30/03/22	CI
Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease	16/03/22	CI
Clarus Therapeutics Holdings, Inc. Announces Strategic Partnerships for JATENZO (testosterone undecanoate) with Vault Health and AssistRx	24/02/22	CI
CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	19/11/21	AQ
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	18/11/21	CI
Clarus Therapeutics Holdings, Inc. Announces Two Notices of Allowance for Patent Claims Covering JATENZO? (testosterone undecanoate)	26/10/21	CI
Clarus Therapeutics : Working With McGill University to Develop Technology for Rare Diseases Associated With Coenzyme-Q10 Deficiencies	16/09/21	MT
BLUE WATE27 : (in thousands, except share and per share data) (Form 8-K)	15/09/21	PU
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	15/09/21	CI
Blue Water Acquisition : Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies	09/09/21	AQ
Clarus Therapeutics, Inc. completed the acquisition of Blue Water Acquisition Corp. from Heights Capital Management, Inc., Lighthouse Investment Partners, LLC and Others in a reverse merger transaction.	08/09/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Clarus Therapeutics Holdings, Inc.

Equities

CRXT

US18271L1070

Highlights

Filters